Non‐alcoholic steatohepatitis (NASH) is a severe form of fatty liver disease. If not treated, it can lead to liver damage, cirrhosis and even liver cancer. However, advances in treatment have remained relatively slow, and there is thus an urgent need to develop appropriate treatments. Hedan tablet (HDP) is used to treat metabolic syndrome. However, scientific understanding of the therapeutic effect of HDP on NASH remains limited. We used HDP to treat a methionine/choline‐deficient diet‐induced model of NASH in rats to elucidate the therapeutic effects of HDP on liver injury. In addition, we used untargeted metabolomics to investigate the effects of HDP on metabolites in liver of NASH rats, and further validated its effects on inflammation and lipid metabolism following screening for potential target pathways. HDP had considerable therapeutic, anti‐oxidant, and anti‐inflammatory effects on NASH. HDP could also alter the hepatic metabolites changed by NASH. Moreover, HDP considerable moderated NF‐κB and lipid metabolism‐related pathways. The present study found that HDP had remarkable therapeutic effects in NASH rats. The therapeutic efficacy of HDP in NASH mainly associated with regulation of NF‐κB and lipid metabolism‐related pathways via arachidonic acid metabolism, glycine‐serine‐threonine metabolism, as well as steroid hormone biosynthesis.

中文翻译：

---

鹤丹片通过调节肝脏代谢物来调节 NF-κB 和脂质代谢相关途径，从而改善非酒精性脂肪性肝炎

非酒精性脂肪性肝炎（NASH）是一种严重的脂肪肝疾病。如果不及时治疗，可能会导致肝损伤、肝硬化甚至肝癌。然而，治疗的进展仍然相对缓慢，因此迫切需要开发适当的治疗方法。鹤丹片（HDP）用于治疗代谢综合征。然而，对于 HDP 对 NASH 的治疗效果的科学认识仍然有限。我们使用 HDP 治疗蛋氨酸/胆碱缺乏饮食诱导的 NASH 大鼠模型，以阐明 HDP 对肝损伤的治疗作用。此外，我们利用非靶向代谢组学研究了HDP对NASH大鼠肝脏代谢物的影响，并在筛选潜在的靶通路后进一步验证了其对炎症和脂质代谢的影响。 HDP 对 NASH 具有显着的治疗、抗氧化和抗炎作用。 HDP 还可以改变 NASH 改变的肝脏代谢物。此外，HDP 显着调节 NF-κB 和脂质代谢相关途径。本研究发现HDP对NASH大鼠具有显着的治疗作用。 HDP对NASH的治疗作用主要与通过花生四烯酸代谢、甘氨酸-丝氨酸-苏氨酸代谢以及类固醇激素生物合成调节NF-κB和脂质代谢相关途径有关。